Workflow
数字健康平台
icon
Search documents
轻松健康集团暗盘大涨超110% 市值逼近百亿元 明日港交所正式挂牌
Zheng Quan Ri Bao Wang· 2025-12-22 11:49
本报讯 (记者袁传玺)12月22日,港股新股轻松健康集团(股票代码:02661.HK)暗盘交易正式启 动,开盘即迎来强势拉升,延续招股阶段的火爆热度。截至暗盘交易时段,公司股价较发行价大涨超 110%,市值逼近百亿元,成为近期港股暗盘市场的亮眼标的。 市场热度背后,是公司扎实的核心竞争力支撑。作为国内领先的综合数字健康平台,轻松健康累计注册 用户达1.684亿,60.4%为20-45岁核心消费群体,用户第13个月留存率高达92.2%。AI技术深度赋能全业 务链条,自研AIcare技术栈贡献线索价值占比超21%。同时,公司业务结构持续优化,2025年上半年健 康服务收入占比达76.7%,近三年年均复合增长率超220%,业绩增长韧性十足。 暗盘交易作为港股新股正式上市前的场外交易环节,其表现被视为新股上市首日走势的重要风向标。轻 松健康暗盘的大幅高开,印证了资本市场对其"AI+全链条数字健康"模式的坚定信心。此前公司全球招 股超额认购倍数高达1421倍。 据悉,轻松健康将于12月23日正式在香港联交所主板挂牌上市。本次IPO募资将重点用于AI技术升级、 健康服务场景拓展及产业链整合,持续深化"检-医-药-康-险" ...
帮主郑重:南向资金火力全开!这三只股被疯狂扫货,宁德时代创纪录!
Sou Hu Cai Jing· 2025-07-13 05:01
Group 1 - Recent southbound capital inflow has surged, with a net purchase of 26.3 billion HKD in one week, an increase of nearly 90% compared to the previous week, and total trading volume exceeding 680 billion HKD [1][3] - The People's Bank of China announced an expansion of the southbound bond connect quota to 1 trillion HKD, allowing more institutional participation, which is seen as a significant boost for Hong Kong stocks [3] - The trend of capital flow is influenced by the acceleration of the internationalization of the RMB, indicating that smart money is positioning itself ahead of market movements [3] Group 2 - Health Road, a leading digital health platform in China, has seen its shares increased to 24.24 million, accounting for 2.75% of total shares, driven by rising health awareness and online medical demand [3] - China Spring, a hidden champion in the private higher education sector, has over 100,000 students across five universities and has aligned its curriculum with market needs, benefiting from government policies promoting digital education [3] - Contemporary Amperex Technology Co., Ltd. (CATL), a global leader in power batteries, has experienced a premium rate increase to 46%, attributed to a deepened cooperation agreement with Geely and significant stock purchases by major investment firms [4] Group 3 - Heng Rui Pharmaceutical has made advancements in breast cancer treatment with its oral estrogen receptor degrader HRS-8080 entering phase III clinical trials, positioning it among the global leaders in this field [4] - Superstar Legend has seen a surge in stock price following Jay Chou's entry into Douyin, with a net purchase of 416 million HKD, reflecting the revaluation of celebrity IP commercial value [4]